Insider at

04

Insider transactions

05
0 buys (P) 1 sells (S) Net: $-90,299 + 5 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

5 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Feb. 23, 2026 VERA S 2,151 $41.98 $90,299 50,947 Direct -4.05% Disposed -27.5% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Feb. 4, 2026 VERA Stock Option (right to buy) Class A Common Stock (50,000) $42.74 Feb. 3, 2036 50,000 Acquired
Feb. 18, 2025 VERA Stock Option (right to buy) Class A Common Stock (53,800) $29.18 Feb. 17, 2035 53,800 Acquired
Jan. 3, 2024 VERA Stock Option (right to buy) Class A Common Stock (350,000) $15.36 Jan. 2, 2034 350,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 1 holding

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
Jan. 8, 2024 VERA No securities beneficially owned 0 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

VERA

M.D. Chief Medical Officer(1)
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2025 $509,000 · $784,942 $1,137,870 $285,040 · $3,000 $2,719,852
2024 $476,615 $120,000 · $3,627,050 $229,138 · $3,000 $4,445,802

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.